韓國舉行諮詢會議，以促進人工智能（AI）在藥物開發中的使用

據Yonhap新聞社報導，該會議將來自經濟和財政部以及其他相關政府機構的官員與包括Daewoong Pharmaceutical在內的領先的製藥公司一起。

South Korea is aiming to become a global leader in artificial intelligence (AI) technology, with a focus on promoting the use of AI in drug development, in response to the intensifying global competition in the bio-health sector, the Ministry of Economy and Finance said on Thursday.

經濟和金融部周四表示，韓國的目標是成為人工智能（AI）技術的全球領導者，重點是促進AI在藥物開發中的使用，以應對生物健康部門的全球競爭。

The ministry held a consultative meeting with private sector stakeholders to discuss ways to foster an environment where AI can be effectively utilized in drug development, Yonhap news agency reported.

據Yonhap News Agency報導，該部與私營部門利益相關者舉行了一次諮詢會議，討論了可以有效利用AI的環境的方法。

Officials from the ministry and other relevant government agencies attended the meeting, along with executives from major pharmaceutical companies, including Daewoong Pharmaceutical.

該部和其他相關政府機構的官員以及包括Daewoong Pharmaceutical在內的主要製藥公司的高管參加了會議。

The meeting served as a platform to listen to the challenges faced by the pharmaceutical industry and to explore directions for public-private cooperation in promoting AI-based drug development and effective data usage, the Ministry said.

該部稱，這次會議是聆聽製藥行業面臨的挑戰，並探討公私合作方面促進基於AI的藥物開發和有效數據使用方面的挑戰。

The global AI biotechnology market is expected to grow over 19 per cent annually, reaching $7.75 billion by 2029, while South Korea currently ranks third in the world in the number of AI bio-related patent applications.

預計全球AI生物技術市場每年增長超過19％，到2029年將達到77.5億美元，而韓國目前在與AI Bio相關的專利申請的數量中排名全球第三。

"AI is rapidly permeating the entire biotechnology industry," the finance ministry said. "It is emerging as a core technology across areas, such as new drug development, protein structure prediction and design, and gene therapy."

財政部說：“ AI正在迅速滲透到整個生物技術行業。” “它正在成為跨領域的核心技術，例如新藥開發，蛋白質結構預測和設計以及基因治療。”

The ministry stressed that countries are now in fierce competition to preemptively secure AI capabilities and apply them effectively in the bio-health field.

該部強調，各國現在處於激烈的競爭中，以先發製人的AI能力並有效地應用於生物健康領域。

In particular, AI-powered drug development is revolutionizing the traditional pharmaceutical research and development process, the ministry said.

該部說，特別是AI驅動的藥物開發正在徹底改變傳統的製藥研究和開發過程。

Meanwhile, South Korea plans to pour 60 billion won (about $40.4 million) by 2028 to expand infrastructure for the development of materials and components technologies crucial for advanced industries, such as AI, the Ministry of Trade, Industry, and Energy said on Thursday.

同時，韓國計劃在2028年之前倒600億韓元（約40040萬美元），以擴大基礎設施，以開發對AI，貿易，工業部和能源部等高級行業至關重要的材料和組件技術。

The investment will be used to build research facilities and equipment for the development and testing of technologies related to materials and components essential for AI, advanced bio, and other future industries, the ministry said.

該部表示，這項投資將用於建造研究設施和設備，以開發和測試與AI，Advanced Bio和其他未來行業所必需的材料和組件相關的技術。

In particular, the government will support the construction of infrastructure for the development of core materials for next-generation AI chips, messenger RNA-based drugs, and others, the ministry said.

該部表示，政府將支持基礎設施的建設，以開發下一代AI芯片，基於Messenger RNA的藥物等核心材料。